Negotiations over IP are acknowledged as one of the biggest bottlenecks in university/industry collaborations. A number of piecemeal schemes aim to overcome this, but a systematic approach is required to create more liquid markets for research outputs
In common with its peers across the pharmaceutical industry, GlaxoSmithKline (GSK) is turning to university collaboration as a source of innovation. Since 2010 it has offered academic partners the chance to become core members of drug discovery teams – sharing the risks and rewards – through its Discovery Partnerships with Academia (DPAc) scheme.
